Bruce Russell
Family Medicine · Schoharie, NYNPI 1336134188
Payments from drug & device makers
Across 456 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Lilly USA, LLC$1K
- AstraZeneca$928
- AbbVie$576
- Pfizer$568
- GSK$549
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,03599%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 78 | $1,508 |
| Lilly USA, LLC | 83 | $1,117 |
| AstraZeneca | 45 | $928 |
| AbbVie(2 entities) | 25 | $576 |
| Pfizer | 40 | $568 |
| GSK | 28 | $549 |
| Johnson & Johnson | 32 | $470 |
| Novo Nordisk | 19 | $439 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $317 |
| Bayer | 10 | $223 |
| Supernus Pharmaceuticals, Inc. | 9 | $178 |
| Idorsia Pharmaceuticals US Inc | 7 | $122 |
| Medicure Pharma Inc. | 2 | $121 |
| Boehringer Ingelheim | 7 | $117 |
| Sunovion Pharmaceuticals Inc. | 14 | $107 |
| Mylan Specialty L.p. | 5 | $97 |
| Kowa Pharmaceuticals America, Inc. | 5 | $89 |
| Tris Pharma Inc | 5 | $85 |
| Amarin Pharma, Inc. | 4 | $74 |
| Astellas Pharma US Inc | 1 | $72 |
| Eisai Inc. | 4 | $59 |
| Novartis | 3 | $59 |
| Exact Sciences | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Insulet Corporation | 1 | $13 |
| Merck | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,131 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 190 | $257,929 |
| MounjaroTirzepatide | 85 | $125,114 |
| FarxigaDapagliflozin Propanediol | 87 | $119,906 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $88,177 |
| EliquisApixaban | 79 | $86,987 |
| XareltoRivaroxaban | 36 | $53,498 |
| JardianceEmpagliflozin | 33 | $40,369 |
| GeodonZiprasidone Hcl | 12 | $39,439 |
| Xigduo XrDapaglifloz Propaned/Metformin | 28 | $36,267 |
| TrulicityDulaglutide | 20 | $35,024 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $18,931 |
| Repatha SureclickEvolocumab | 12 | $18,901 |
| UbrelvyUbrogepant | 17 | $16,769 |
| VascepaIcosapent Ethyl | 30 | $16,724 |
| Repatha SyringeEvolocumab | 12 | $12,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $439 | $257,929190 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,117 | $160,138105 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $928 | $144,364124 claims |
| PfizerEliquis, Geodon | $568 | $126,42691 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $549 | $96,28583 claims |
| Johnson & JohnsonXarelto | $470 | $53,49836 claims |
| Boehringer IngelheimJardiance | $117 | $40,36933 claims |
| AbbVieUbrelvy | $576 | $16,76917 claims |
| MerckBelsomra | $13 | $10,36923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Schoharie
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.